AbbVie Inc Submits Marketing Application to FDA
AbbVie Inc, a biotechnology company focused on pharmaceutical products, has submitted a marketing application to the FDA for TrenibotulinumtoxinE, a treatment aimed at addressing glabellar lines.
Key Details
- Product: TrenibotulinumtoxinE
- Indication: Treatment of glabellar lines
- Regulatory Status: Marketing application submitted to FDA
Upcoming Earnings Release
AbbVie is scheduled to release its Q1 2025 earnings, which is expected to be a significant event for investors.
Company Performance
- Stock price has fluctuated over time, with periods of growth and decline
- Overall, AbbVie remains a prominent player in the biotechnology sector